Table A-3.

Descriptive Statistical Summary in the Unmatched Sample by Instrument Variable – Before or After March 2000 When Olanzapine was Approved by FDA to Treat Bipolar Disorder (219 olanzapine users and 689 lithium users)

CHARACTERISTICS	After March 00	Before March 00	P–Value
FEMALE	57.500	56.044	0.682
NORTHEAST	32.143	27.002	0.112
NORTHCEN	30.000	22.763	0.020
WEST	2.500	2.983	0.685
SOUTH	30.000	42.700	0.0003
FFS	31.071	40.031	0.010
HMO	12.143	7.064	0.012
POSNOCAP	12.857	7.692	0.013
POSCAP	26.429	29.670	0.317
PPO	17.500	15.542	0.458
USERID	36.429	18.367	< 0.0001
AGE	38 (16)	42 (14)	0.0014
COUNTMDC1	5 (3)	6 (3)	0.321
ABUSE1	1 (3)	0 (3)	0.149
EPILEP1	0 (0)	0 (0)	0.731
HEART1	0 (2)	0 (2)	0.248
DIAB1	1 (4)	1 (4)	0.998
THERAPY1	6 (10)	4 (10)	0.027
NUMBD1	10 (15)	11 (14)	0.063
NUMMH1	17 (21)	16 (17)	0.285
NUMBDIP1	0 (1)	0 (1)	0.023
NUMBDOP1	9 (15)	11 (13)	0.045
NUMMHIP1	0 (1)	0 (1)	0.0015
NUMMHOP1	17 (21)	16 (16)	0.338
SUMBD1	2,093 (4,854)	1,852 (4,179)	0.470
SUMBDIP1	1,392 (4,053)	912 (3,499)	0.086
SUMBDOP1	701 (1,603)	940 (1,820)	0.047
SUMMH1	3,182 (5,775)	2,456 (5,063)	0.070
SUMMHIP1	1,885 (4,588)	1,126 (3,834)	0.016
SUMMHOP1	1,297 (2,063)	1,330 (2,418)	0.830
SUMCL1	6,140 (8,461)	5,308 (8,708)	0.175